Tengion (Tengion) Debt-to-Asset : 3.55 (As of Sep. 2014)

View and export this data going back to 2010. Start your Free Trial

What is Tengion Debt-to-Asset?

Tengion's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2014 was $0.68 Mil. Tengion's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2014 was $33.44 Mil. Tengion's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2014 was $9.62 Mil. Tengion's debt to asset for the quarter that ended in Sep. 2014 was 3.55.

Tengion Debt-to-Asset Historical Data

The historical data trend for Tengion's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tengion Debt-to-Asset Chart

Tengion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Debt-to-Asset

Get a 7-Day Free Trial

0.59

0.36

0.28

0.91

1.05

Tengion Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Debt-to-Asset	Get a 7-Day Free Trial															0.90	1.05	1.55	2.15	3.55

Competitive Comparison of Tengion's Debt-to-Asset

For the Biotechnology subindustry, Tengion's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tengion's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tengion's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Tengion's Debt-to-Asset falls into.

Tengion Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Tengion's Debt-to-Asset for the fiscal year that ended in Dec. 2013 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.329	+	25.623)	/	25.724
	=	1.05

Tengion's Debt-to-Asset for the quarter that ended in Sep. 2014 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.68	+	33.442)	/	9.621
	=	3.55

Tengion (GREY:TNGNQ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Tengion Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Tengion's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tengion (Tengion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tengion Inc (GREY:TNGNQ) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

3929 Westpoint Boulevard, Suite G, Winston-Salem, NC, USA, 27103

Website

http://www.tengion.com

Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.

Executives

John L Miclot	director, officer: President and CEO	5005 OLD ORCHARD LANE, GIBSONIA PA 15044
Lorin Randall	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
A Brian Davis	officer: Chf. Fin. Offr, VP Fin.	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Medtronic Inc	10 percent owner	710 MEDTRONIC PKWY, MINNEAPOLIS MN 55432
Johan Christenson	10 percent owner	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Staffan Lindstrand	10 percent owner	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Richard Kuntz	director	MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Diane Jorkasky	director	60 MANOR AVENUE, WELLESLEY MA 02482
Mark Stejbach	officer: VP and Chief Commercial Offcr	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Steven Nichtberger	director, officer: President and CEO	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Johnson & Johnson	10 percent owner	ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Oak Investment Partners Xi L P	10 percent owner	901 MAIN AVENUE, SUITE 600, NORWALK CT 06851

Tengion (Tengion) Headlines

From GuruFocus

Tengion Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-20-2010